CASP3 and breast cancer: As shown in Figs. 6 and 7, PAX used alone dose-dependently increased the number of cells with active caspase-3 in MCF7 BC cells, as follows ctr. = 2.4%, PAX2.0 = 4.56%, PAX4.0 = 6.69%.